Preoperative immune-therapy combination shows promise in skin cancer

Source: Nature, October 2022

Treatment with the drugs relatlimab and nivolumab before the surgical removal of a type of cancer called melanoma resulted in tumours becoming inviable in 57% of individuals, and no severe adverse effects were observed. People with a favourable treatment response had a better survival outcome than did those who did not respond.
READ THE ORIGINAL FULL ARTICLE